GlobalData on MSN2d
Dyne’s DMD trial advances patient mobility and dystrophin expression
The Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an ...
BioSpace2d
Dyne’s Duchenne Exon Skipping Oligomer Shows ‘Differentiated’ Clinical Effect
Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...
Dyne announces new long-term data from Phase 1/2 DELIVER trial of DYNE-251
Dyne Therapeutics (DYN) announced new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented ...
Nasdaq2d
Dyne : Phase 1/2 Trial Of DYNE-251 In DMD Shows Sustained Functional Improvements Through 18 Months
announced new long-term clinical data from its Phase 1/2 DELIVER trial of DYNE-251 demonstrating unprecedented and sustained functional improvement at the selected registrational dose of 20 mg/kg ...
Nasdaq2d
Dyne Therapeutics Reports Promising Long-Term Data for DYNE-251 in Duchenne Muscular Dystrophy with Plans for Accelerated Approval Submission
Dyne Therapeutics reports positive long-term data for DYNE-251 in Duchenne muscular dystrophy, aiming for U.S. accelerated approval in 2026. Dyne Therapeutics announced new long-term clinical data ...
Dyne reports new long-term data from Phase 1/2 DELIVER trial of DYNE-251
Dyne Therapeutics (NASDAQ:DYN) on Monday  reported new long-term clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 demonstrating “unprecedented and sustained functional improvement at ...
Dyne: Accelerated Approval Of DYNE-101 Might Be Possible With Surrogate Biomarker
Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.